INJ slides more than 10% as heavy selling hits despite ETF proposals and solid protocol metrics

INJ slides more than 10% as heavy selling hits despite ETF proposals and solid protocol metrics
Injective slides 10.17% today to $7.82

Injective (INJ) fell 10.17% today as heavy intraday selling pressure outweighed recent positive protocol and governance developments. The decline is reinforced by the asset testing the lower end of a near-term support zone between $7.7 and $7.92, even as the overall technical structure remains bullish above major moving averages.

INJ price prediction
24H -0.41%
$7.28
48H -7.25%
$6.78
7D -11.22%
$6.49
1M -11.35%
$6.48
3M -65.94%
$2.49
6M -78.39%
$1.58
12M 19.97%
$8.77
Current price: $7.31 0.68 10.17%
Real-time Data 09:58
Daily range 6.84 Arrow from to Icon 7.44
Weekly range 6.56 Arrow from to Icon 8.44
Loading...

Highlights

  • Injective generated $3.58 million in annual protocol revenue and advanced a governance proposal to preset core exchange gas costs.
  • Multiple U.S. ETF applications featuring INJ, some with staking features, were submitted by 21Shares, Canary Capital, and REX-Osprey, but none represent direct ETF approval.
  • INJ/USD trades between $7.7 and $7.92 under short-term selling pressure, with a projected five-day range of $6.61 to $9.49 and overbought momentum signals present.

Protocol revenue and ETF filings weigh against broad market selling

Injective reported annual protocol revenue of $3.58 million and introduced governance proposal IIP-709 to preset gas costs for core exchange messages. Multiple U.S. ETF proposals involving INJ were filed by firms including 21Shares, Canary Capital, and REX-Osprey, with some including staking strategies, though none signify direct ETF approval. Proof-of-stake issuance and continued buyback and burn mechanisms were also noted, accompanied by ongoing compliance and governance activities, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that the sharp 10.17% drop in INJ challenges the recent bullish momentum, despite positive protocol revenue and ETF filing news. He sees the price testing key support at $7.7 amid ongoing volatility and heavy intraday selling pressure. Kharitonov highlights conflicting technical signals, with overbought readings from the CCI and Bull/Bear Power countering bullish moving average alignment. He remains cautious on the sustainability of recent buyback and burn mechanisms, given the lack of strong institutional inflows from pending ETF proposals. "Until we see more conviction in volume and regulatory clarity, INJ remains vulnerable to a further drawdown below $7.7," he warns.
Viktoras Karapetjanc, expert at Traders Union, believes the bullish structure on INJ remains intact despite today's volatility. He views annual protocol revenue and active governance proposals as strong fundamental drivers. The introduction of ETF strategies by reputable firms signals growing institutional interest and long-term adoption. Karapetjanc is confident that the current pullback offers attractive entry points for forward-looking investors. "Further growth is expected, and the market offers multiple setups for those who capitalize on these consolidation phases," he says.
Jainam Mehta, market strategist, sees mixed signals for INJ as price hovers between $7.7 support and $7.92 resistance. He points out that momentum indicators are split, suggesting a potential contrarian setup if sentiment shifts. Mehta notes that volatility remains elevated, making tactical trades on breakout or breakdown likely to appeal to active traders. "A potential breakout above $7.92 could offer short-term upside, but caution is warranted on failed retests of $7.7," he states.
Injective asset chart
Injective price dynamics. Source: TradingView.

Divergent technical signals as bullish structure meets overbought risk

INJ/USD is trading above its 20-day ($7.7), 50-day ($6.83), and 200-day ($5.15) moving averages, reflecting a bullish structure across all timeframes. The pair is currently positioned between the near-term floor at $7.7 and resistance at the Ichimoku Kijun level of $7.92, with both medium- and long-term alignment remaining bullish. Momentum indicators are mixed; MACD and ADX forecast further upside, and RSI at 61.36 is also in buy territory. However, CCI and Bull/Bear Power both signal overbought conditions, with BBP at 1.03 showing buyers dominate intraday action. Awesome Oscillator remains positive, Stochastic RSI reads neutral, and the Hull Moving Average has a sell forecast, highlighting signal divergence. After a downside gap of about 1%, INJ/USD trades near session lows at $7.82, with volatility at 9.23%, reflecting heavy intraday selling against broader positive momentum.

Earlier, analysts noted that Injective's bullish momentum was underpinned by strong technical alignment and increasing institutional engagement. The current article adds that despite today’s selloff and short-term support tests, INJ continues to exhibit robust technical structure, with the key level to watch being a potential breakout above $7.92 for renewed upside.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.